Jump to content
Powered by

Cellzome Announces Achievement of Second Milestone in Epigenetics Collaboration with GSK

Cellzome announced today that it has achieved the second milestone in its epigenetics alliance with GlaxoSmithKline. The milestone triggers a payment of an undisclosed amount from GSK and follows only two months after the first milestone was achieved.

The strategic collaboration in epigenetics was announced in March 2010 and gives GSK exclusive access to Cellzome’s proprietary Episphere™ technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Under the terms of the agreement, the companies work together using Cellzome’s Episphere™ technology platform, to identify selective small-molecule drug candidates against targets from four different epigenetic target classes. The companies share operational responsibility for the programs until identification of drug candidates, at which stage GSK will assume responsibility for any further preclinical and clinical development and commercialisation.
Tim Edwards, CEO of Cellzome, said: “Achieving the second milestone in this collaboration in less than a year after its start demonstrates how well our technology is suited to address drug discovery for epigenetic targets. It also shows how well the scientists from Cellzome and GSK work together. ”
Cellzome is eligible for milestone payments and tiered royalties for each programme in this epigenetic collaboration with GSK. Milestone payments over the course of the collaboration could reach over €475 million if all programmes under the alliance are successfully developed and commercialised.

More information:

Tim Edwards
Chief Executive Officer
Tel: +49 (0) 6221-137 57-100
E-Mail: press(at)cellzome.com
Website address: https://www.gesundheitsindustrie-bw.de/en/article/press-release/cellzome-announces-achievement-of-second-milestone-in-epigenetics-collaboration-with-gsk